Endocyte (NASDAQ:ECYT) Inc., with no marketed products, plunged the most in more than two years after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer. Endocyte, Inc. (NASDAQ:ECYT) shares after opening at $6.75 moved to $7.05 on last trade day and at the end of the day closed at $6.62. Company price to sales ratio in past twelve months was calculated as 4.22 and price to cash ratio as 2.22. Endocyte, Inc. (NASDAQ:ECYT) showed a negative weekly performance of -63.10%.
Merrimack Pharmaceuticals (NASDAQ:MACK) posted its quarterly earnings results on Thursday. The company reported ($0.27) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.30) by $0.03, American Banking News.com reports. The company had revenue of $13.03 million for the quarter, compared to the consensus estimate of $11.93 million. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) shares fell -8.01% in last trading session and ended the day on $6.43. MACK return on equity ratio is recorded as 349.10% and its return on assets is -80.40%. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) yearly performance is 39.18%.
Immunomedics Inc. (NASDAQ:IMMU) intends to grant the underwriters a 30-day option to purchase additional shares of common stock. All of the shares to be sold in the offering are being sold by Immunomedics, with the proceeds to fund the Company’s Phase III clinical trial for patients with advanced pancreatic cancer and its ongoing Phase II expansion trials for IMMU-132 and IMMU-130, as well as for working capital and general corporate purposes. Wells Fargo Securities, LLC and Jefferies LLC are acting as joint book-running managers. Immunomedics, Inc. (NASDAQ:IMMU) shares moved down -21.98% in last trading session and was closed at $3.23, while trading in range of $3.19 – $3.35. Immunomedics, Inc. (NASDAQ:IMMU) year to date (YTD) performance is -29.78%.
Seattle Genetics Inc. (NASDAQ:SGEN) reported Q1 EPS of ($0.13), $0.08 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $68.3 million versus the consensus estimate of $64.62 million. Seattle Genetics, Inc. (NASDAQ:SGEN) weekly performance is -7.88%. On last trading day company shares ended up $34.50. Seattle Genetics, Inc. (NASDAQ:SGEN) distance from 50-day simple moving average (SMA50) is -25.28%. Analysts mean target price for the company is $45.77.